Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





2016 State and City TB Indicators Report										Related Pages
										The National TB Indicators Report publishes key process and outcomes measures for TB control programs in the United States to evaluate progress towards TB elimination.  CDC selected the indicators used in the report, in cooperation with partners in state and local health departments. Indicators cover a wide range of important TB topics, including TB incidence, treatment completion for TB disease, known-HIV status, and treatment initiation and completion for contacts diagnosed with latent TB infection.
These data can help TB control programs:
evaluate progress in TB prevention and control,
monitor TB program performance,
assess needs for education and technical assistance, and
identify areas that need improvementCDC provides funding for TB control activities in 50 U.S. states and 9 cities. Data for calculating these indicators come from the National TB Surveillance System and the Aggregate Reports for Program Evaluation.  For more information on the National TB Indicators Project, visit National TB Indicators Project Fact Sheet.
Highlights from the 2016 report are below.  For more details, view the full report pdf icon[PDF].  If you need additional state-specific data not available in this report, contact your state TB control office.

**TB Incidence**
Measuring the number of new TB cases each year is the best overall indicator of progress towards TB elimination.  TB elimination is defined as less than 1 case per million persons per year.  In 2016, TB incidence in the United States was 2.9 overall TB cases per 100,000 persons (30 per million).
In 2016:
9 states and 9 cities reported incidences above the national average of 2.9 cases per 100,000.
41 states were at or below the national average.The National TB Indicators Reportpdf icon contains additional details, including incidence rates for states and cities.
**Completion of Therapy**

Fully treating and preventing further spread of TB disease is key to TB control and elimination.  Although treatment for TB disease can be challenging to complete, there are several ways to increase treatment completion.  CDC has set a 2020 national target of 95.0% of TB cases completing a full treatment regimen for TB disease in 12 months or less.  The most recent national average, in 2014, for treatment completion for TB disease is 90.1%.
TB disease treatment is complex, and can take several months to complete.  It can take up to 2 years to have complete treatment information for TB patients.  Therefore, the most recent information available on completion of therapy is from 2014.
The National TB Indicators Reportpdf icon contains additional details, including treatment completion rates for states and cities.
**HIV Status**

Tuberculosis is a serious health threat for people living with HIV. People living with HIV are more likely to become sick with TB disease if they are exposed and become infected. Measuring the number of TB patients who are also tested for HIV and have a known HIV status is important to save lives and interrupt the spread of TB and HIV to others. CDC has set a 2020 national target of having HIV status known among at least 98.0% of TB cases. In 2016, the national average of TB cases having known HIV status was 89.9%.
The National TB Indicators Reportpdf icon contains additional details, including percentages of known HIV status for TB patients for states and cities.

**Treatment for Latent TB Infection Among Contacts**
TB programs work to identify people who may have been exposed to people with TB disease (often referred to as “contacts”), and offer testing and treatment for latent TB infection. People with latent TB infection can be treated to prevent the development of TB disease.  Identifying and treating people with latent TB infection is critical to achieving TB elimination.
**Treatment Initiation Among Contacts:**
CDC has set a 2020 national target of initiating treatment for 91.0% of people diagnosed with latent TB infection found during contact investigations.  The most recent national average was 72.6%.
The National TB Indicators Reportpdf icon contains additional details on latent TB infection treatment initiation rates for states and cities.

**Treatment Completion Among Contacts:**
CDC has set a 2020 national target of treatment completion for 81.0% of people diagnosed with latent TB infection found during contact investigations who started treatment.  The most recent national average was 75.3%.
The National TB Indicators Reportpdf icon contains additional details on latent TB infection treatment completion rates for states and cities.Additional ResourcesNational TB Indicators Reportpdf icon
National TB Indicators Project Fact Sheet
National TB Program Objectives and Performance Targets for 2020
TB Data and Statistics
							
					
						Page last reviewed:  June 4, 2018					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue